New Weight Loss Tablet Treatments: What's Coming and What You Need to Know

If you have been following the world of weight loss treatment over the last few years, you will have heard plenty about injectable medications like Wegovy and Mounjaro. These GLP-1 treatments have changed the conversation around weight management, offering clinically meaningful results for many patients. But a new chapter is opening, and it does not involve a needle.

Oral GLP-1 medications, weight loss treatments you swallow rather than inject, are now entering the UK market. Rybelsus is already available on prescription for type 2 diabetes, and higher-dose options specifically approved for weight management are expected to follow later in 2026. For patients who have been hesitant about injections, or who simply want a more convenient daily routine, this is a significant development.

This article is a plain-English guide to what oral weight loss medications are, how they compare to injectables, what is currently approved or in the pipeline for the UK, and what the evidence actually says.

What are oral weight loss medications?

Oral weight loss medications in this category are tablet-based versions of the same class of drugs currently used in injectable weight management treatments. Rather than being administered via a weekly injection under the skin, they are taken by mouth, typically once daily.

The most relevant ones right now belong to a group called GLP-1 receptor agonists. GLP-1 stands for glucagon-like peptide-1, a hormone your body naturally produces in response to food. These medications mimic that hormone's effect: they signal to your brain that you are full, slow down how quickly your stomach empties, and help regulate blood sugar levels. The result, when combined with lifestyle changes, is a meaningful reduction in appetite and, for many patients, significant weight loss.

The key point is that the mechanism is the same whether the medication is injected or swallowed. The delivery method is what changes. [1]

How do weight loss tablets differ from injections?

The most obvious difference is how you take them. Injectable GLP-1 medications like Wegovy (semaglutide) and Mounjaro (tirzepatide) are administered once a week via a small pen injector. Oral GLP-1 medications are taken as a daily tablet.

Beyond convenience, there are some meaningful clinical differences to understand. Oral semaglutide has lower bioavailability than its injectable counterpart, meaning the body absorbs a smaller proportion of the active compound when it passes through the digestive system. [3] This is why oral versions typically require higher doses to achieve comparable effects, and why some oral tablets come with specific instructions around timing and water/food intake to maximise absorption.

Currently, injectable formulations have a longer and more robust clinical evidence base for weight loss outcomes. Wegovy's injectable form, for instance, is backed by the extensive STEP trial programme, which demonstrated average weight loss of around 15% over 68 weeks. [2] Oral options are newer to this indication, and while trial results are promising, the long-term data is still catching up.

That said, the significance of a tablet option should not be underestimated. Needle anxiety is a real barrier for many patients, and daily oral dosing fits naturally into existing routines in a way that a weekly injection may not.

“Oral GLP-1 treatments represent a significant step forward in improving access to obesity care. While injectable therapies have transformed outcomes for many patients, not everyone feels comfortable using injections long term. A tablet option may help reduce barriers for people who are needle-averse, travel frequently, or struggle with the practicalities of injectable treatment.

From a clinician’s perspective, expanding the range of formulations available allows us to tailor treatment more closely to the individual patient. Improved convenience and flexibility may also support long-term adherence, which is one of the biggest challenges in obesity management. Obesity is a chronic condition, and sustainable treatment options are essential if we want to improve long-term health outcomes.”

— Dr Saira Bano, GP with a special interest in metabolic health and obesity at SwiftDoctor

What weight loss tablets are currently available or coming to the UK?

The landscape is moving quickly, so here is an accurate picture of where things stand as of mid-2026.

1. Rybelsus (oral semaglutide 7 mg / 14 mg)

Rybelsus is the only oral GLP-1 medication currently approved in the UK, but it is licensed for the management of type 2 diabetes, not obesity. Some patients may be prescribed it off-label by private clinics, but it is not licensed as a weight management treatment in its own right. [3]

2. Oral Wegovy (semaglutide 25 mg)

A higher-dose oral semaglutide specifically developed for weight management was approved by the US FDA in December 2025. It is currently under review by the MHRA, with a UK decision expected in late 2026. Unlike Rybelsus, this formulation was studied and approved specifically for weight loss, which is an important distinction. [4]

3. Foundayo (orforglipron)

Foundayo, developed by Eli Lilly under the generic name orforglipron, received FDA approval in April 2026 and represents a notable innovation. Unlike existing oral GLP-1 medications, it is a small-molecule, non-peptide drug, which means it does not face the same absorption challenges as peptide-based options. This allows it to be taken at any time of day without any restrictions on food or water intake. Eli Lilly has submitted Foundayo for approval in over 40 countries; UK approval is possible in late 2026 or 2027, but a confirmed timeline has not been announced. [5]

What does the evidence say about oral GLP-1 weight loss tablets?

The clinical evidence is still developing compared to injectables, but the results so far are genuinely encouraging.

For oral semaglutide at the 25 mg dose specifically developed for weight management, the OASIS 1 trial published in the New England Journal of Medicine reported average weight loss of around 15% over 68 weeks in overweight or obese adults without type 2 diabetes. [6] This is a meaningful result and comparable in scale to what has been seen with injectable semaglutide.

For orforglipron (Foundayo), Phase 3 trial data showed participants losing around 8% of their body weight at 40 weeks at the highest dose studied, with researchers noting that weight loss had not yet plateaued by the end of the trial period, suggesting results could be more significant with extended treatment. [7]

It is worth being clear that injectable GLP-1 medications still have the longer and more established evidence base, particularly for cardiovascular outcomes and long-term durability. Oral options are promising and the trial data is robust, but they are newer in this specific indication and the full picture will become clearer over time.

Who might be suitable for oral weight loss medication?

Oral GLP-1 medications will not be the right choice for everyone, but there are patient profiles where they may be a particularly good fit.

Patients with injection anxiety are an obvious group. For someone who would genuinely benefit from GLP-1 treatment but has been unwilling to consider injectables, a tablet removes a significant barrier. Similarly, patients who travel frequently, have demanding schedules, or simply prefer the familiarity of taking a daily tablet may find oral options easier to sustain over the long term.

That said, suitability for any prescription weight loss medication is determined by clinical assessment. Factors including BMI, weight-related health conditions, current medications, and medical history all inform the decision. It is not a case of simply choosing a format you prefer; a clinician needs to determine whether oral GLP-1 treatment is appropriate for your individual circumstances and, once any oral options become MHRA-approved for weight management, which specific medication is most suitable.

As with all GLP-1 treatments, oral options are intended to be used alongside a reduced-calorie diet and increased physical activity, not as a standalone solution.

How SwiftDoctor can help you explore your options

SwiftDoctor is a doctor-led service that keeps pace with developments in weight loss treatment, including the emerging category of oral GLP-1 medications. Our clinicians are well placed to advise on whether injectable or oral treatment is more appropriate for your individual circumstances, taking into account your health history, goals, and personal preferences.

Consultations are fast, discreet, and completed entirely online, so you can get expert guidance without waiting for a GP appointment or visiting a clinic in person. As new oral weight loss medications receive MHRA approval in the UK, SwiftDoctor will be positioned to offer them to eligible patients promptly.

If you are curious about your options, explore our weight loss treatments here.

Frequently asked questions

Are oral GLP-1 medications as effective as injections for weight loss? 

The evidence is promising. The OASIS 4 trial showed average weight loss of around 15% over 68 weeks with oral semaglutide at 25 mg, while orforglipron (Foundayo) is still building its long-term dataset. Injectables currently have a more established track record, particularly for cardiovascular outcomes, but the gap is narrowing as trial programmes mature.

Will oral weight loss tablets eventually replace injections? 

Not necessarily. Injectables and tablets are likely to serve different patient needs rather than one replacing the other. Some patients will always prefer the convenience of a once-weekly injection over a daily tablet, while others will find the opposite. The expansion of oral options means more patients can access effective treatment in a format that suits them.

Do oral GLP-1 tablets have the same side effects as injections? 

Broadly yes, since the mechanism is the same. Nausea and gastrointestinal symptoms are the most commonly reported effects with both formats. Some oral tablets also have specific instructions around timing and food intake that injectables do not, which is worth factoring into your daily routine.

How long will I have to wait for oral weight loss tablets in the UK? 

Rybelsus is already available on prescription, though it is licensed for type 2 diabetes rather than weight management. Oral Wegovy is currently under MHRA review with a decision expected in late 2026, and Foundayo's UK timeline is yet to be confirmed. A consultation with SwiftDoctor can keep you informed as new options become available.

Can I switch from an injectable GLP-1 to a tablet version? 

Potentially, once MHRA-approved oral options for weight management are available in the UK. Whether a switch is appropriate depends on your individual circumstances, treatment history, and clinical assessment. This is a conversation best had with your prescribing clinician when the time comes.

Disclaimer & Editorial Standards

The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.

The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.

Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.

Sources

1. Nauck, M.A. et al. (2020). GLP-1 receptor agonists in the treatment of type 2 diabetes. Nature Reviews Endocrinology, 17, 255–274. https://pmc.ncbi.nlm.nih.gov/articles/PMC8085572/ 

2. Wilding, J.P.H. et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384, 989–1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 

3. Electronic Medicines Compendium (2026). Rybelsus 7 mg and 14 mg tablets: Summary of Product Characteristics. Novo Nordisk. https://www.medicines.org.uk/emc/product/14388/smpc 

4. Novo Nordisk (2025). Wegovy pill approved in the US as first oral GLP-1 for chronic weight management in adults. Press release, 05 January 2026. https://www.prnewswire.com/news-releases/novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-now-broadly-available-across-america-302652205.html 

5. Eli Lilly and Company (2026). FDA approves Lilly's Foundayo (orforglipron). Press release, 1 April 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill  

6. Wharton, S. et al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine, 393(11), 1077–1087. https://www.nejm.org/doi/10.1056/NEJMoa2500969  

7. Wharton, S. et al. (2023). Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. New England Journal of Medicine, 389, 877–888. https://www.nejm.org/doi/full/10.1056/NEJMoa2302392